Evidence map›Paper›PMID 24088737›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013

Novel methylation biomarker panel for the early detection of pancreatic cancer.

Joo Mi Yi, Angela A Guzzetta, Vasudev J Bailey, Stephanie R Downing, Leander Van Neste, Katherine B Chiappinelli, Brian P Keeley, Alejandro Stark, Alexander Herrera, Christopher Wolfgang and 7 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02079363 (Cell-free DNA Promoter Hypermethylation in Plasma From Patients With Pancreatic Adenocarcinoma, Compared to Patients With Pancreatitis and Pancreatitis and Patients Screened for, But Not Having Pancreatic Adenocarcinoma."), which is not on this map. Cited by 93 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02079363 unknown statusnot on this map

Cell-free DNA Promoter Hypermethylation in Plasma From Patients With Pancreatic Adenocarcinoma, Compared to Patients With Pancreatitis and Pancreatitis and Patients Screened for, But Not Having Pancreatic Adenocarcinoma."

TypeobservationalSponsorAalborg University HospitalRan2013 to 2018Enrolled330ConditionsPancreatic Diseases, Pancreatic Neoplasms, PancreatitisArmsNo interventions, this is an observational study
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 1 synthesis or guideline pooled it, 211 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Joo Mi Yi *Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Angela A Guzzetta *Department of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Vasudev J BaileyDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD, Baltimore, MD, USA.
Stephanie R DowningDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Leander Van NesteMDxHealth, Ghent, Belgium.
Katherine B ChiappinelliDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Brian P KeeleyDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD, Baltimore, MD, USA.
Alejandro StarkDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD, Baltimore, MD, USA.
Alexander HerreraDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Christopher WolfgangDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Emmanouil P PappouDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Christine A Iacobuzio-DonahueDepartment of Pathology, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Michael G GogginsDepartment of Pathology, The Sol Goldman Pancreatic Research Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
James G HermanDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Tza-Huei WangDepartment of Biomedical Engineering, Johns Hopkins School of Medicine, Baltimore, MD, Baltimore, MD, USA.
Stephen B BaylinDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Nita AhujaDepartment of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins University · USDongnam Institute of Radiological & Medical Sciences · KR

Funding

Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6M
TARGETING EARLY CHANGES FOR NEW SCREENING STRATEGIESP50CA058184 · NCI · JOHNS HOPKINS UNIVERSITY · PI BISWAL, SHYAM · 1992 to 2013
$30.5M
ValidationU54CA151838 · NCI · JOHNS HOPKINS UNIVERSITY · PI POMPER, MARTIN G, SEARSON, PETER C · 2010 to 2014
$11.9M
DNA Methyltrasferase Gene Expression in Colon CancerR01ES011858 · NIEHS · JOHNS HOPKINS UNIVERSITY · PI BAYLIN, STEPHEN B., EASWARAN, HARIHARAN · 2002 to 2023
$11.5M
Clinical and Laboratory Research Training for Surgical OncologistsT32CA126607 · NCI · JOHNS HOPKINS UNIVERSITY · PI CAMERON, ANDREW M. · 2008 to 2024
$6.0M
Multiplexed Detection of Cell Free DNA Biomarkers for CancerR01CA155305 · NCI · JOHNS HOPKINS UNIVERSITY · PI WANG, TZA-HUEI JEFF · 2011 to 2015
$1.7M
Epigenetic markers involved in colorectal cancer recurrence and metastasesK23CA127141 · NCI · JOHNS HOPKINS UNIVERSITY · PI AHUJA, NITA · 2008 to 2012
$705k
COMMUNITY-BASED APPROACHES TO TOBACCO CONTROLF32CA069731 · NCI · STANFORD UNIVERSITY · PI RIBISL, KURT M. · 1996 to 1997
–
NCI NIH HHS CA058184NCI NIH HHS F32 CA069731NCI NIH HHS K23 CA127141NCI NIH HHS NIH NCI K23CA127141NCI NIH HHS P30 CA006973NCI NIH HHS P30CA006973NCI NIH HHS P50 CA058184NCI NIH HHS R01 CA155305NCI NIH HHS R01CA155305NCI NIH HHS T32 CA126607NCI NIH HHS T32CA126607NCI NIH HHS U54 CA151838NCI NIH HHS U54CA151838NIEHS NIH HHS NIEHS R01ES011858NIEHS NIH HHS R01 ES011858
6 · The paper itself

Abstract

purposePancreatic cancer is the fourth leading cause of cancer deaths and there currently is no reliable modality for the early detection of this disease. Here, we identify cancer-specific promoter DNA methylation of BNC1 and ADAMTS1 as a promising biomarker detection strategy meriting investigation in pancreatic cancer. EXPERIMENTAL

designWe used a genome-wide pharmacologic transcriptome approach to identify novel cancer-specific DNA methylation alterations in pancreatic cancer cell lines. Of eight promising genes, we focused our studies on BNC1 and ADAMTS1 for further downstream analysis, including methylation and expression. We used a nanoparticle-enabled methylation on beads (MOB) technology to detect early-stage pancreatic cancers by analyzing DNA methylation in patient serum.

resultsWe identified two novel genes, BNC1 (92%) and ADAMTS1 (68%), that showed a high frequency of methylation in pancreatic cancers (n = 143), up to 100% in PanIN-3 and 97% in stage I invasive cancers. Using the nanoparticle-enabled MOB technology, these alterations could be detected in serum samples (n = 42) from patients with pancreatic cancer, with a sensitivity for BNC1 of 79% [95% confidence interval (CI), 66%-91%] and for ADAMTS1 of 48% (95% CI, 33%-63%), whereas specificity was 89% for BNC1 (95% CI, 76%-100%) and 92% for ADAMTS1 (95% CI, 82%-100%). Overall sensitivity using both markers is 81% (95% CI, 69%-93%) and specificity is 85% (95% CI, 71%-99%).

conclusionsPromoter DNA methylation of BNC1 and ADAMTS1 is a potential biomarker to detect early-stage pancreatic cancers. Assaying the promoter methylation status of these genes in circulating DNA from serum is a promising strategy for early detection of pancreatic cancer and has the potential to improve mortality from this disease.

Indexed as

DNA MethylationADAM ProteinsADAMTS1 ProteinBiomarkers, TumorCarcinoma in SituCell Line, TumorCell MovementCell ProliferationCpG IslandsDNADNA-Binding ProteinsEarly Detection of CancerEpigenesis, GeneticFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticADAM ProteinsADAMTS1 ProteinADAMTS1 protein, humanBiomarkers, TumorBNC1 protein, humanDNADNA-Binding ProteinsTranscription Factors

Identifiers

PMID24088737
PMCPMC4310572
OpenAlexW2153765299

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.